Cargando…
The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
Immunotherapy, particularly immune checkpoint inhibitors, have become widely used in various settings across many different cancer types in recent years. Whilst patients are often treated on the basis of the primary cancer type and clinical stage, recent studies have highlighted disparity in respons...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713699/ https://www.ncbi.nlm.nih.gov/pubmed/36466910 http://dx.doi.org/10.3389/fimmu.2022.1030147 |
_version_ | 1784842066610618368 |
---|---|
author | Conway, Jordan W. Braden, Jorja Wilmott, James S. Scolyer, Richard A. Long, Georgina V. Pires da Silva, Inês |
author_facet | Conway, Jordan W. Braden, Jorja Wilmott, James S. Scolyer, Richard A. Long, Georgina V. Pires da Silva, Inês |
author_sort | Conway, Jordan W. |
collection | PubMed |
description | Immunotherapy, particularly immune checkpoint inhibitors, have become widely used in various settings across many different cancer types in recent years. Whilst patients are often treated on the basis of the primary cancer type and clinical stage, recent studies have highlighted disparity in response to immune checkpoint inhibitors at different sites of metastasis, and their impact on overall response and survival. Studies exploring the tumor immune microenvironment at different organ sites have provided insights into the immune-related mechanisms behind organ-specific patterns of response to immunotherapy. In this review, we aimed to highlight the key learnings from clinical studies across various cancers including melanoma, lung cancer, renal cell carcinoma, colorectal cancer, breast cancer and others, assessing the association of site of metastasis and response to immune checkpoint inhibitors. We also summarize the key clinical and pre-clinical findings from studies exploring the immune microenvironment of specific sites of metastasis. Ultimately, further characterization of the tumor immune microenvironment at different metastatic sites, and understanding the biological drivers of these differences, may identify organ-specific mechanisms of resistance, which will lead to more personalized treatment approaches for patients with innate or acquired resistance to immunotherapy. |
format | Online Article Text |
id | pubmed-9713699 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97136992022-12-02 The effect of organ-specific tumor microenvironments on response patterns to immunotherapy Conway, Jordan W. Braden, Jorja Wilmott, James S. Scolyer, Richard A. Long, Georgina V. Pires da Silva, Inês Front Immunol Immunology Immunotherapy, particularly immune checkpoint inhibitors, have become widely used in various settings across many different cancer types in recent years. Whilst patients are often treated on the basis of the primary cancer type and clinical stage, recent studies have highlighted disparity in response to immune checkpoint inhibitors at different sites of metastasis, and their impact on overall response and survival. Studies exploring the tumor immune microenvironment at different organ sites have provided insights into the immune-related mechanisms behind organ-specific patterns of response to immunotherapy. In this review, we aimed to highlight the key learnings from clinical studies across various cancers including melanoma, lung cancer, renal cell carcinoma, colorectal cancer, breast cancer and others, assessing the association of site of metastasis and response to immune checkpoint inhibitors. We also summarize the key clinical and pre-clinical findings from studies exploring the immune microenvironment of specific sites of metastasis. Ultimately, further characterization of the tumor immune microenvironment at different metastatic sites, and understanding the biological drivers of these differences, may identify organ-specific mechanisms of resistance, which will lead to more personalized treatment approaches for patients with innate or acquired resistance to immunotherapy. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9713699/ /pubmed/36466910 http://dx.doi.org/10.3389/fimmu.2022.1030147 Text en Copyright © 2022 Conway, Braden, Wilmott, Scolyer, Long and Pires da Silva https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Conway, Jordan W. Braden, Jorja Wilmott, James S. Scolyer, Richard A. Long, Georgina V. Pires da Silva, Inês The effect of organ-specific tumor microenvironments on response patterns to immunotherapy |
title | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy |
title_full | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy |
title_fullStr | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy |
title_full_unstemmed | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy |
title_short | The effect of organ-specific tumor microenvironments on response patterns to immunotherapy |
title_sort | effect of organ-specific tumor microenvironments on response patterns to immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713699/ https://www.ncbi.nlm.nih.gov/pubmed/36466910 http://dx.doi.org/10.3389/fimmu.2022.1030147 |
work_keys_str_mv | AT conwayjordanw theeffectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT bradenjorja theeffectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT wilmottjamess theeffectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT scolyerricharda theeffectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT longgeorginav theeffectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT piresdasilvaines theeffectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT conwayjordanw effectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT bradenjorja effectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT wilmottjamess effectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT scolyerricharda effectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT longgeorginav effectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy AT piresdasilvaines effectoforganspecifictumormicroenvironmentsonresponsepatternstoimmunotherapy |